Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 4/20 | 0.35 |
| ▸ | CA1 | P00915 | 4/20 | 0.35 |
| ▸ | CA9 | Q16790 | 4/20 | 0.35 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 2/20 | 0.34 |
| ▸ | SSTR5 | P35346 | 7/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.34 |
| ▸ | PDE5A | O76074 | 1/20 | 0.33 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5512110 | 0.89 | GRM2 (0.39) | ALDH1A1TP53 | |
| SCHEMBL12768203 | 0.86 | TSHR (0.38) | ALDH1A1F10 | |
| SCHEMBL5511797 | 0.86 | MAPK14 (0.34) | ALDH1A1F10 | |
| SCHEMBL12768201 | 0.83 | ALDH1A1 (0.32) | ALDH1A1F10 | |
| SCHEMBL1640224 | 0.83 | ROCK2 (0.43) | CA1CA2F10 | |
| SCHEMBL14522065 | 0.81 | MAP2K2 (0.33) | ALDH1A1F10 | |
| SCHEMBL1640669 | 0.81 | ROCK2 (0.46) | ALDH1A1CA1CA2 | |
| SCHEMBL1640888 | 0.81 | ROCK2 (0.46) | ALDH1A1CA1CA2 | |
| SCHEMBL1640672 | 0.81 | ROCK2 (0.46) | ALDH1A1CA1CA2 | |
| SCHEMBL3841699 | 0.80 | KMT2A (0.33) | TP53F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2094272-B1 | NITROGEN CONTAINING SUBSTITUTED HETEROCYCLES AS PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARM INC (US) | 2014-03-26 | — | — | EP | disclosed |
| US-20110098247-A1 | Substituted Dihydroquinazolines as Platelet ADP Receptor Inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| US-7834023-B2 | Substituted dihydroquinazolines as platelet ADP receptor inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-11-16 | — | — | US | disclosed |
| WO-2008036843-A2 | NITROGEN CONTAINING SUBSTITUTED HETEROCYCLES AS PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-03-27 | — | — | WO | disclosed |
| EP-1812429-A2 | SUBSTITUTED 2H-1,3-BENZOXAZIN-4(3H)-ONES | Portola Pharmaceuticals, Inc. (US) | 2007-08-01 | — | — | EP | disclosed |
| US-7205296-B2 | Substituted 2H-1,3-benzoxazin-4(3H)-ones | PORTOLA PHARMACEUTICALS, INC. (US) | 2007-04-17 | — | — | US | disclosed |
| US-7205296-B2 | Substituted 2H-1,3-benzoxazin-4(3H)-ones | PORTOLA PHARMACEUTICALS, INC. (US) | 2007-04-17 | — | — | US | disclosed |
| US-7205296-B2 | Substituted 2H-1,3-benzoxazin-4(3H)-ones | PORTOLA PHARMACEUTICALS, INC. (US) | 2007-04-17 | — | — | US | disclosed |
| WO-2006039212-A2 | SUBSTITUTED 2H-1,3-BENZOXAZIN-4(3H)-ONES | PORTOLA PHARMACEUTICALS, INC. (US) | 2006-04-13 | — | — | WO | disclosed |
| US-20060069093-A1 | Substituted 2H-1,3-benzoxazin-4(3H)-ones | PORTOLA PHARMACEUTICALS, INC. (US) | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069093-A1 | Substituted 2H-1,3-benzoxazin-4(3H)-ones | TBXAS1, TBXA2R, SERPINC1 | ALDH1A1 704/4885TP53 4740/4885CA12 2391/4885 |
| US-20110098247-A1 | Substituted Dihydroquinazolines as Platelet ADP Receptor Inhibitors | TBXA2R, F2R, PTGER1 | ALDH1A1 284/4885TP53 3875/4885CA12 4849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.